Why Nyxoah SA’s (NYXH) Stock Is Up 16.23%
As of Thursday, September 03, Nyxoah SA’s NYXH share price has surged by 16.23%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Commentary & Analysis
Why Nyxoah SA’s (NYXH) Stock Is Up 5.78%
As of Monday, August 10, Nyxoah SA’s NYXH share price has surged by 5.78%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Nyxoah SA’s (NYXH) Stock Is Up 9.16%
As of Friday, August 07, Nyxoah SA’s NYXH share price has surged by 9.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Nyxoah SA’s (NYXH) Stock Is Down 7.09%
As of Thursday, August 06, Nyxoah SA’s NYXH share price has dipped by 7.09%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Nyxoah SA’s (NYXH) Stock Is Down 5.37%
As of Tuesday, July 07, Nyxoah SA’s NYXH share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $154.3 | $416.1 | 25% |
|
| Shares Out (Mil) | 65.1 | 41.6 | 54% |
|
| Institutional Ownership | 33.0% | 83.1% | 13% |
|
| Float (Mil) | 50.9 | 35.6 | 47% |
|
| Beta | 0.95 | 0.88 | 57% |
|
| Avg Daily Volume (000s) | 105 | 333 | 37% |
|
| Price Change (52-week) |
(74.4%) | 65.0% | 8% |
|
| Growth | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 159.6% | 11.8% | 100% |
|
| Net Income (5yr) | (47.8%) | (5.9%) | 7% |
|
| EPS (5yr) | (27.4%) | 10.2% | 9 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.6%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 3 | 4 | |
| Current EPS | ($0.378) | ($1.406) | ($0.973) | |
| Month Ago EPS | ($0.386) | ($0.966) | ($0.545) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.420) | ($1.765) | ($1.330) | |
| Year/Year Chg | (42.8%) | (49.4%) | (82.9%) | |
| Financials | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $25 | $119 | 14% |
|
| Net Income (TTM) (Mil) | ($110) | ($9) | 10% |
|
| EPS (TTM) | ($2.467) | ($0.400) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($3) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $47 | $1 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $42 | $22 | 38% |
|
| Enterprise Value (Q1) (Mil) | $119 | $371 | 22% |
|
| Valuation | NYXH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.59 | 3.00 | 41% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.6 | na |
|
| Ratios | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 60.2% | 58.5% | 73% |
|
| Net Margin | (443.2%) | (6.9%) | 2% |
|
| ROA | (66.6%) | (13.4%) | 9% |
|
| ROE | (121.1%) | (13.6%) | 8% |
|
| Liabilities to Assets | 50.7% | 46.1% | 43% |
|
| F-Score | 2 | 4 | 7% |
|
Nyxoah SA did not pass any screens on 9/2/2026.
